睿智医药(300149) - 2022 Q4 - 年度财报(更新)

Important Notice The company's 2022 annual financial report received a standard unqualified audit opinion, and the Board of Directors proposed no profit distribution for the year - The company's 2022 annual financial report was audited by Ernst & Young Hua Ming LLP and received a standard unqualified opinion[1] - The Board of Directors' 2022 profit distribution plan is to not distribute cash dividends, bonus shares, or convert capital reserves into share capital[1] Company Overview This section provides an overview of the company's fundamental information, core business, financial performance, and shareholder structure Company Profile This section provides basic information including the company's stock ticker 'WITS MEDICINE', stock code '300149', listing exchange, and Board Secretary contact details | Item | Information | | :--- | :--- | | Stock Ticker | WITS MEDICINE | | Stock Code | 300149 | | Listing Exchange | Shenzhen Stock Exchange | | Board Secretary | Xu Jian | Main Business and Strategic Adjustments The company strategically focuses on pharmaceutical R&D and manufacturing services (CRO/CDMO), having divested its prebiotic business, with CRO/CDMO accounting for 89.8% of revenue - The company's strategy focuses on pharmaceutical R&D and manufacturing services (CRO/CDMO), having divested its prebiotic business during the reporting period[2][6] - The pharmaceutical R&D and manufacturing services (CRO/CDMO) segment, as the core business, achieved operating revenue of 1.191 billion yuan, accounting for 89.8% of the company's total revenue during the reporting period[3] Pharmaceutical R&D and Manufacturing Services (CRO/CDMO) CRO services cover chemical and biological drugs from discovery to preclinical research, while CDMO focuses on large molecules after small molecule divestiture - Chemical CRO business provides comprehensive services for early discovery of small molecule drugs, incorporating cutting-edge technologies like AI-assisted drug design and PROTAC[3] - Biological CRO business covers biologics R&D, pharmacokinetics and early toxicology, and biological and pharmacological efficacy studies[3][4][5] - The company sold Kaihui Pharmaceutical, which operated small molecule CDMO, in March 2022, with future CDMO business primarily focusing on large molecules[6] Micro-ecological Health (Divested) The company's original micro-ecological health segment, primarily prebiotic products, completed its equity transfer on June 9, 2022 - To focus on its core business, the company completed the equity transfer of its prebiotic business on June 9, 2022[6] Key Accounting Data and Financial Indicators In 2022, operating revenue decreased by 21.54%, while net profit attributable to shareholders increased by 190.15% due to asset disposal gains, turning profitable | Indicator | 2022 | 2021 | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (Yuan) | 1,326,584,320.12 | 1,690,677,943.33 | -21.54% | | Net Profit Attributable to Shareholders (Yuan) | 362,625,006.97 | -402,245,074.78 | 190.15% | | Net Profit Attributable to Shareholders After Non-recurring Items (Yuan) | -623,419,492.95 | -422,303,938.34 | -47.62% | | Net Cash Flow from Operating Activities (Yuan) | 262,460,386.22 | 378,219,891.25 | -30.61% | | Basic Earnings Per Share (Yuan/share) | 0.73 | -0.81 | 190.12% | | Weighted Average Return on Net Assets | 16.83% | -18.40% | 35.23% | | Total Assets (Yuan) | 3,807,937,141.71 | 4,217,591,526.68 | -9.71% | | Quarter | Operating Revenue (Yuan) | Net Profit Attributable to Shareholders (Yuan) | | :--- | :--- | :--- | | Q1 | 386,301,922.70 | 9,470,996.67 | | Q2 | 300,594,594.81 | 947,113,666.40 | | Q3 | 345,340,861.01 | 66,807,165.81 | | Q4 | 294,346,941.60 | -660,766,821.91 | Share Capital and Shareholder Information As of the end of the reporting period, the company had 26,368 common shareholders, with the top three holding significant stakes - Total common shareholders at the end of the reporting period were 26,368[10] | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | Beihai Baben Venture Capital Co., Ltd. | 13.69% | 68,441,800 | | Hangzhou Cixuan Liangjia Investment Management Partnership (Limited Partnership) | 10.24% | 51,185,660 | | Shanghai Ruiyun Enterprise Management Center (Limited Partnership) | 7.07% | 35,325,429 | Significant Matters and Future Outlook This section covers the impact of the Shanghai epidemic on revenue, the effect of strategic divestiture on net profit, and outlines future development strategies - During the reporting period, the company's business was impacted by the Shanghai epidemic, leading to a 21.54% year-over-year decrease in operating revenue[11] - Despite the decline in operating revenue, net profit attributable to the parent company significantly increased, primarily due to investment gains from the divestiture of the prebiotic business to focus on core operations[11] - Future development strategy includes continuously strengthening CRO technological advantages, expanding domestic market presence, attracting talent, and leveraging CRO/CDMO synergy to accelerate CDMO business growth[11]